Dear Dr. Renukaprasad A R,  Do you know abemaciclib reduces the risk of distant recurrence by approximately 34% in breast cancer patients? Abemaciclib is the most recent oral cyclin-dependent kinase 4 and 6 inhibitor used for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC). It has also been shown to reduce the rate of recurrence among breast cancer patients. Have you missed the webinar? Don't worry! We have saved the recording just for YOU! We hope you find the session useful. | 
No comments:
Post a Comment